Navigation Links
Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
Date:4/10/2013

SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice. Using its proprietary high-throughput Cellular Redistribution Assay (CRA), Omeros believes that it alone has identified compounds that functionally interact with GPR17 and has patents pending that are broadly directed to any such compounds active at the receptor.

Having discovered compounds that functionally interact with GPR17, Omeros previously showed that GPR17 antagonists promote generation of mature oligodendrocytes, the cells that produce myelin. Myelin is a key component of the proper functioning of the central nervous system, and myelin deficiency is a hallmark of a large number of neurodegenerative autoimmune diseases, including MS. In this EAE model, animals treated with GPR17-targeting compounds, compared to untreated animals, significantly improved mean clinical scores, which quantify disease progression by measuring motor dysfunction and are used as a surrogate indicator of demyelination.

"Our GPCR platform – built around our proprietary CRA – continues to unlock wholly new drug targets, and we expect that our sole knowledge of the identities of their interacting compounds together with our patent positions will give Omeros exclusive control of those receptors," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "GPR17 is one of those
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
2. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
3. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
4. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
5. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
6. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
7. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
11. Omeros is Not Aware of Any Justification for Share Price Movement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
(Date:2/27/2015)... -- Boston Scientific Corporation (NYSE: BSX ) is ... Conference on March 10 in Miami Beach ... vice president and chief financial officer, and Susie ... a 25-minute question and answer session regarding the company ... Following a 5-minute break, a question and answer session ...
(Date:2/27/2015)... MISSISSAUGA, ON , Feb. 27, 2015 /CNW/ - Covalon ... advanced medical technologies company, today announced financial results for ... For the three months ended December 31, 2014, ... for the quarter was $229,820 or $0.02 per share.  ... Pedlar , said "I am very pleased with the ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:2/28/2015)... In recent years Medical Marijuana has continuously been ... a way for them to expand their patient base without ... Since the FDA still lists Cannabis as a Schedule 1 ... physicians that can help guide them when recommending a ... in Santa Cruz, CA is a leader in the small, ...
(Date:2/28/2015)... AB (PRWEB) February 28, 2015 The ... is now a distributor of the machine. The Heart ... of their license, like a franchise model. The goal ... prevent and reverse heart disease. To buy External ... Fit Clinic can help individuals through this process and ...
(Date:2/28/2015)... NB (PRWEB) February 28, 2015 ... center software suite for Asterisk, are pleased to announce ... highly successful 5.7 and 5.8 versions of Q-Suite, this ... well as a number of new features to the ... Q2 2015. , Q-Suite 5.9 will add features to ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
(Date:2/28/2015)... 28, 2015 How would you ... , There are all kinds of different leaders, ... awareness of the advantages and applications of different ... launching a new product this spring called The ... the connection between personality type, leadership, and success. ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
... be "alarmingly dismal" with over 180 million urban poor having ... an industry analysis. ,At least 300 additional urban ... annually to cater to the needs of 215 million urban ... of Commerce and Industry of India (ASSOCHAM). ,In ...
... of colorectal cancers getting missed out in patients undergoing ... a gastroenterologist// or a surgeon. This was disclosed by ... researchers. ,This study was conducted on 12,487 ... Ontario along with her team. According to this study, ...
... flu in their county. This was disclosed by Faizullah Kakar, ... H5N1 virus was found in the eastern province of Nangarhar. ... diagnosed as the case of malaria. The Nangarhar area has ... ,Culling of birds was initiated earlier this week ...
... risk of mercury in canned albacore tuna in women and ... tuna in women and children. This follows a recent report ... cans of albacore tuna tested contained mercury more than the ... of canned albacore tuna per week can be had by ...
... and intolerance to gluten.// ,Inflammatory ... inflammations in muscular tissue. Coeliac disease is ... ,Inflammatory myopathies are inflammatory infiltrates ... includes polymyositis, dermatomyositis, and inclusion-body myositis. Little ...
... the heart gets its distinguishing shape? Shape may be formed ... and shape, all of which react to// influences from the ... bulges later on to develop into cardiac chambers. ... journal PLoS Biology, Heidi Auman, Deborah Yelon, and colleagues found, ...
Cached Medicine News:Health News:Urban Poor in Dire Need of Proper Healthcare: Report 2Health News:Inflammatory Myopathy may Indicate Intolerance to Gluten 2
Donor Screen & Confirmation Kit...
... method for Dimension integrated chemistry systems ... in vitro diagnostic test intended to ... (TPSA) in human serum or plasma. ... in the detection of prostate cancer ...
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
The BioCheck hCG ELISA is intended for the quantitative determination of human chorionic gonadotropin (hCG) concentration in human serum. The assay is for use in the early diagnosis of pregnancy in a...
Medicine Products: